Home » Newsletters » BioWorld

BioWorld

March 19, 2008

View Archived Issues

Possible Vasculitis Case Halts Heplisav Trials, Dynavax Falls

The news sent shares of Dynavax (NASDAQ:DVAX) plunging 58.6 percent, closing Tuesday at $2.16, down $3.06. (BioWorld Today) Read More

Nuvelo Halting Alfimeprase After Phase II Study Failure

Approval Letter on Ceftobiprole Sends Basilea Shares Plunging

Alimera Closes $30M Financing, Boosts Stake in Medidur FA

BioNumerik's Tavocept Shows Trend Only in 'Small' Phase III

Prometic, Sartorius Pact Taps into Asian Markets

Other News To Note

Clinic Roundup

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 16, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...